A framework for blood biomarker discovery in MS - PubMed
3 hours ago
- #clinical utility
- #blood biomarkers
- #multiple sclerosis
- Multiple sclerosis (MS) biomarkers can enhance pathophysiological understanding, diagnostics, prognostication, and personalized treatment.
- Technological advances enable detection of low-concentration blood biomarkers, with some showing correlation between blood and cerebrospinal fluid (CSF).
- Omics technologies facilitate discovery of molecular panels that may reflect disease heterogeneity through interdependencies.
- Neurofilament light (NfL) is a successfully implemented MS biomarker in clinical practice, with others like GFAP showing promise.
- Standardization in discovery and validation, along with demonstration of clinical utility, is needed for regulatory approval and widespread adoption of new biomarkers.